Published in Ann Oncol on December 01, 2011
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep (2013) 0.96
First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Fam Cancer (2015) 0.87
Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease. Cancer Res Treat (2013) 0.85
Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model. J Clin Invest (2015) 0.81
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine. EPMA J (2015) 0.80
Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review. Can Urol Assoc J (2015) 0.78
Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Therap Adv Gastroenterol (2013) 0.78
Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report. Target Oncol (2012) 0.78
Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma. J Kidney Cancer VHL (2015) 0.78
Words of wisdom: re: pilot trial of sunitinib therapy in patients with von hippel-lindau disease. Eur Urol (2013) 0.76
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group. Oncotarget (2016) 0.75
Systemic Sunitinib Malate Treatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease. Ophthalmol Retina (2017) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
von Hippel-Lindau disease. Lancet (2003) 6.20
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina (2007) 1.46
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology (2002) 1.45
Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol (2003) 1.42
Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med (1998) 1.27
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest (2008) 1.07
Antiangiogenic therapy for von Hippel-Lindau disease. JAMA (2004) 1.03
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg (2001) 11.58
Uncertainty in predictions of the climate response to rising levels of greenhouse gases. Nature (2005) 7.46
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet (2000) 5.28
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci (1991) 4.53
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Lumbar puncture needn't be a headache. BMJ (1997) 3.65
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Inhibition by acetylene of conventional hydrogenase in nitrogen-fixing bacteria. Nature (1976) 3.11
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun (2005) 3.06
Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology (2000) 3.03
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev (2000) 3.01
Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Int J Tuberc Lung Dis (1997) 2.53
An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg (2000) 2.50
Family preservation using multisystemic therapy: an effective alternative to incarcerating serious juvenile offenders. J Consult Clin Psychol (1992) 2.43
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19
Vacuum pack technique of temporary abdominal closure: a 7-year experience with 112 patients. J Trauma (2000) 2.13
Intracisternal A-particle genes in Mus musculus: a conserved family of retrovirus-like elements. Mol Cell Biol (1981) 2.07
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2011) 2.05
Successful therapy for trilateral retinoblastoma. Am J Ophthalmol (1992) 2.03
The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med (2000) 1.92
Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol (2006) 1.92
Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer (1997) 1.86
Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol (2010) 1.81
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res (2001) 1.80
Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery (1999) 1.79
Reversible hypothyroidism in Addison's disease. Lancet (1972) 1.78
Impact of interruptions and distractions on dispensing errors in an ambulatory care pharmacy. Am J Health Syst Pharm (1999) 1.77
Primary extradural meningiomas: a report on nine cases and review of the literature from the era of computerized tomography scanning. J Neurosurg (2000) 1.75
Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat (2005) 1.74
Development of vaccines for prevention of botulism. Biochimie (2000) 1.73
The surgical treatment of metastatic spinal tumors within the intradural extramedullary compartment. J Neurosurg (1996) 1.71
Oral aspirin in postoperative pain: a quantitative systematic review. Pain (1999) 1.71
Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. J Neurosurg (2000) 1.70
Systematic review of the use of honey as a wound dressing. BMC Complement Altern Med (2001) 1.63
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62
Changes in lung function following the surgical treatment of bullous emphysema. Q J Med (1970) 1.61
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer (2012) 1.61
Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol (2000) 1.60
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer (2000) 1.58
Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content. AJR Am J Roentgenol (1995) 1.58
Transthoracic vertebrectomy for metastatic spinal tumors. J Neurosurg (1998) 1.55
Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol (2001) 1.53
Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough? Pain (2001) 1.51
Hiccups and human purpose. Nature (1990) 1.50
Confidence, uncertainty and decision-support relevance in climate predictions. Philos Trans A Math Phys Eng Sci (2007) 1.49
Renal outcome 25 years after donor nephrectomy. J Urol (2001) 1.47
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res (2000) 1.47
Routine neuroimaging in retinoblastoma for the detection of intracranial tumors. Arch Ophthalmol (2001) 1.46
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer (2008) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Postoperative swelling of pericranial pedicle graft producing intracranial mass effect. Report of two cases. J Neurosurg (1999) 1.41
Field efficacy of sweet corn hybrids expressing a Bacillus thuringiensis toxin for management of Ostrinia nubilalis (Lepidoptera: Crambidae) and Helicoverpa zea (Lepidoptera: Noctuidae). J Econ Entomol (2001) 1.40
Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun (1998) 1.39
Neuropathies in AIDS. Br J Hosp Med (1991) 1.38
Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Res (2000) 1.37
Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res (2000) 1.36
Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. Ann Surg Oncol (1996) 1.36
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol (2012) 1.35
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer (2009) 1.32
Modeling Pichia pastoris growth on methanol and optimizing the production of a recombinant protein, the heavy-chain fragment C of botulinum neurotoxin, serotype A. Biotechnol Bioeng (2000) 1.31
Low-temperature-induced changes in intracellular fatty acid fluxes in Dunaliella salina. Arch Biochem Biophys (1985) 1.30
Risk of death from Alzheimer's disease in a community population of older persons. Am J Epidemiol (1991) 1.28
Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res (2000) 1.27
Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res (1996) 1.26
The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol (1998) 1.26
Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosomes Cancer (1992) 1.24
Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am J Pathol (2000) 1.22
Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol (2000) 1.21
Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun (2001) 1.20
Utility of postmortem magnetic resonance imaging in clinical neuropathology. Arch Pathol Lab Med (1994) 1.19
Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol (2011) 1.18
Purification and characterization of the sequence-specific endonuclease Bam HI. J Biol Chem (1979) 1.18
Non-Hodgkin's lymphoma involving the gynecologic tract: a review of 88 cases. Adv Anat Pathol (2001) 1.17
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res (2000) 1.17
Molecular cloning of a cDNA encoding aspartate aminotransferase-P2 from lupin root nodules. Plant Mol Biol (1992) 1.16
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol (1998) 1.16
Nanostructured polymer scaffolds for tissue engineering and regenerative medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.15
Regional ketone body utilization by rat brain in starvation and diabetes. Am J Physiol (1986) 1.15
Single-stage posterior vertebrectomy and replacement combined with posterior instrumentation for spinal metastasis. J Neurosurg (1996) 1.15
Molecular cloning of the gene encoding developing seed L-asparaginase from Lupinus angustifolius. Plant Mol Biol (1992) 1.13
Isolation and quantitative analysis of phosphatidylglycerol and glycolipid molecular species using reversed-phase high-performance liquid chromatography with flame ionization detection. J Chromatogr (1985) 1.13
Interventions for prevention of drug use by young people delivered in non-school settings. Cochrane Database Syst Rev (2006) 1.12
Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst (1975) 1.12
Chondrosarcoma of the spine: 1954 to 1997. J Neurosurg (1999) 1.12
MR imaging of papillary tumor of the pineal region. AJNR Am J Neuroradiol (2007) 1.11
Upper limits on a stochastic background of gravitational waves. Phys Rev Lett (2005) 1.11
Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein e-deficient mice. Stroke (2001) 1.10
Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon (2003) 1.10
Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis (1996) 1.09
Simultaneous anterior-posterior approach to the thoracic and lumbar spine for the radical resection of tumors followed by reconstruction and stabilization. J Neurosurg (2001) 1.09
Craniospinal dissemination of central neurocytoma. Report of two cases. J Neurosurg (1997) 1.08
Use of hemostatic powder (Hemospray) in the management of refractory gastric variceal hemorrhage. Endoscopy (2013) 1.08
Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis (1996) 1.08